Biotagenics is a clinical microbiomics company developing therapeutics and companion diagnostics for the management and treatment of diseases associated with microbiota dysbiosis. Our initial focus is Inflammatory Bowel Disease.
We are biopharmaceutical executives, microbiologists, immunologists, and gastroenterologists. Our microbiomics platform is coupled with extensive clinical correlative data as well as metagenomic and metaproteomic analyses of patient samples.
Biotagenics is identifying therapeutic targets that have the potential to restore symbiosis and modify the course of disease. Our therapeutic strategy is based on precision targeting of the microbiome using our validated recombinant antibody technology.
Thomas Cirrito Ph.D. is also CEO and co-founder of Filament BioSolutions, a clinical nutrition company developing a portfolio of medical and functional foods. Dr. Cirrito is also an inventor and founder of Immunovent, a development stage biotechnology company developing next-generation, non-invasive allergy diagnostics. Dr. Cirrito previously served as Vice President of Research and Development and Director of Business Development at Stemline Therapeutics (NASDAQ: STML). Dr. Cirrito joined Stemline as the second full-time employee, and was responsible for business development, preclinical, intellectual property, manufacturing, analytical, and operations. Prior to joining Stemline, Dr. Cirrito was a biopharmaceuticals equities analyst at Piper Jaffray. Dr. Cirrito received a B.A. in Biological Sciences and a Ph.D. in Immunology from Washington University (St. Louis, Missouri). He currently serves on the Scientific and Business Advisory Board of the Alzheimer's Drug Discovery Foundation, and is an adjunct faculty member at NYU. He serves as an investor and mentor to numerous life science companies.
Ali Riazi, Ph.D. is a molecular biologist with over 15 years of experience in academia and biotechnology industry at various scientific and executive positions. He has extensive experience in antibody development and engineering, functional genomics, and biologics manufacturing and bioprocessing. He co-founded AbCelex Technologies in 2010 and served as its Chief Scientific Officer. Dr. Riazi established AbCelex’s antibody platform for antimicrobial applications leading to development of AbCelex’s first product. Prior to AbCelex, he worked at a start up biotechnology company as a senior scientist and director of R&D. During his academic tenure at the Hospital for Sick Children and University of Toronto he led a team of scientists engaged in cardiovascular disease and stem cell engineering. Dr. Riazi has authored numerous peer-reviewed publications and conference proceedings and is an inventor on several patents. He received his Ph.D. in Genetics and Molecular Biology from the University of Alberta in 1998.
Alain Stintzi, Ph.D. is a professor with the Department of Biochemistry, Microbiology and Immunology, a member of the Ottawa Institute of Systems Biology, and Vice-Dean of Graduate and Postdoctoral Studies at the Faculty of Medicine, University of Ottawa. Dr. Stintzi obtained his PhD in Molecular and Cellular Biology at the Louis-Pasteur University, France (1997). He was subsequently a Postdoctoral fellow at the Department of Chemistry, University of California at Berkeley. In 2000, he was appointed Assistant Professor at the Department of Veterinary Pathobiology, Oklahoma State University. Dr. Stintzi has considerable experience in systems biology approaches to study the role of the gut microbiota in infectious and chronic diseases, especially Campylobacter jejuni gastroenteritis and inflammatory bowel disease. Dr. Stintzi has published over 63 articles and book chapters and has contributed to more than 150 scientific and educational conferences.
Daniel Figeys, Ph.D. is Chair and Professor in the Department of Biochemistry, Microbiology and Immunology, at the University of Ottawa. He is a Tier-1 Canada Research Chair in Proteomics and Systems Biology and an International Professor in the Chinese Academy of Sciences. He was the founding Director of the Ottawa Institute of Systems Biology and directed the institute for 10 years. Prior to joining the University of Ottawa, Daniel was Senior Vice President Systems biology and Lead Profiling from 2000-2004 at MDS-Proteomics, a privately held company. Daniel obtained a B.Sc. and a M.Sc. in chemistry from the Université de Montréal. He obtained a Ph.D. in chemistry from the University of Alberta and did his postdoctoral studies at the University of Washington. His laboratory has published over 150 papers and has been cited over 10,000 times.
Dr. Mack is currently a Professor with the Department of Pediatrics in the Faculty of Medicine, at the University of Ottawa; Chief of Pediatric Gastroenterology, Hepatology & Nutrition at the Children's Hospital of Eastern Ontario; and Senior Scientist at the CHEO Research Institute. He is the Pediatric Lead of the Clinical Affairs Committee of the Canadian Association of Gastroenterology and currently Deputy-Chair of the Canadian Children Inflammatory Bowel Disease Network. Dr. Mack obtained his medical degree from the University of Toronto in 1983. He was appointed to faculty at the University of Nebraska School of Medicine in the Unites States in 1991. Dr. Mack completed his Pediatric Residency training at the Children’s Hospital of Eastern Ontario, and Residency training and Pediatric Gastroenterology Fellowship at the Hospital for Sick Kids in Toronto. His research Interests include pediatric Inflammatory Bowel Disease and the intestinal microbiome in pediatric Crohn’s disease and ulcerative colitis.
Ulcerative Colitis and Crohns’ Disease (collectively referred to as IBD) are severe GI disorders caused by inflammation.
Both conditions are significant unmet medical needs of increasing incidence and frequent patient hospitalizations.
The human microbiome is a key functional component to disease and human health. Recent advances in high-throughput sequencing have opened up the opportunity to use this dynamic collection of bacteria as a diagnostic and therapeutic target.
Biotagenics has developed proprietary biomarker discovery platform using specialized methods to analyze genome and proteome of the intestinal microbial ecosystems.
Utilizing our biobank of pediatric IBD intestinal and stool samples along with our single-domain antibody discovery platform, we aim to commercialize novel diagnostics and highly specific therapeutics that target bacteria associated with the disease conditions.
Biotagenics has assembled a platform to develop pathobiont-specific biologics and companion diagnostics. Our powerful metagenomics, proteomics, and metabolomics discovery platform combined with unique, clinically well-defined tissue biobanks allows generation of diagnostics and effective treatment for IBD.
Biotagenics has secured an exclusive, worldwide license to the technologies developed by our Founders at the University of Ottawa. Biotagenics continues to collaborate with the University of Ottawa and Children’s Hospital of Eastern Ontario Research Institute to develop these technologies and discover new diagnostic and therapeutic opportunities in IBD and other diseases mediated by dysbiosis.
Biotagenics is actively seeking innovative technologies and opportunities for industry partnerships.
Please Contact email@example.com to discuss partnership or licensing opportunities.
Biotagenics is located in Toronto at MaRS Center, West Tower
661 University Avenue
Suite 1300, Toronto, Ontario M5G 0B7
We can be reached via info (at) biotagenics.com
or by phone at 647-243-5224.